Small-molecule drugs have several advantages that are complementary to, and possibly synergistic with, biologic approaches for anticancer immunotherapy. This Review provides an overview of immunological pathways that can best be targeted with small molec
In the context of an ageing inflammatory bowel disease (IBD) population, cardiovascular comorbidities become particularly relevant. Novel small molecule drugs (SMDs) for the treatment of moderate‐to‐severe IBD have been recently approved, including Janus kinase (JAK) inhibitors and sphingosine‐1‐...
Volume: 21, P: 18-19 Targeted protein degradation comes of age Enabling protein degradation with small-molecule drugs has emerged as an innovative approach to the development of therapeutics against otherwise intractable targets. Two landmark studies that established the therapeutic potential of heterobi...
Large molecule drugs largely fall into four categories: (1) hormones and other replacement proteins, (2) cytokines (signaling molecules employed by the immune system), (3) vaccines, and (4) antibodies. Hormones Insulin is the founding member of the large molecule hormone drug group, used to ...
Organ-on-a-chip technology has been used in testing small-molecule drugs for screening potential therapeutics and regulatory protocols. The technology is expected to boost the development of novel therapies and accelerate the discovery of drug combinations in the coming years. This has led to the ...
biologics small molecule drugs biosimilars antibody-drug conjugates patient access to drugs drug cost 1. Introduction Man has had a long and excruciating experience with ill-health or disease ([1]). In the same vein has been the struggle for cures, a quest that will continue for as long as...
Small molecule drugs have been the mainstay of the conventional pharmaceutical industry for generations. These small molecule active pharmaceutical ingredients (APIs) can be made by organic synthesis methods or microbial fermentation. Small molecule APIs include vitamin C, steroids, and aminoglycoside and...
Small-molecule kinase inhibitors: an analysis of FDA- approved drugs. Drug Discov Today 2016;21:5-10.Wu P, Nielsen TE, Clausen MH. Small-molecule kinase inhibitors: An analysis ... W Peng,TE Nielsen,MH Clausen - 《Drug Discovery Today》 被引量: 118发表: 2016年 Small-molecule kinase ...
Drugs From Discovery to Approval An abstract is unavailable. Somberg,J. - 《American Journal of Therapeutics》 被引量: 76发表: 2004年 Optimization of small molecule drugs binding to highly polar target sites: lessons from the discovery and development of neuraminidase inhibitors. Binding affinity ...
The biological rationale for targeting protein–protein interactions as a therapeutic strategy is strong, but identifying viable small-molecule drugs to achieve this has proved highly challenging. This article uses examples of successful discovery effort